

Spectrophotometric determination of L- α -glycerylphosphorylcholine in pharmaceutical formulations and industrial equipment cleaning rinse water with the WAKO Phospholipids C assay kit

Pavel Anatolyevich Nikolaychuk

Laboratory of Chemical Analysis, Quality Assurance Department, LLC “Velpharm”, Kurgan, Russian Federation

ABSTRACT

A simple spectrophotometric method for the determination of L- α -glycerylphosphorylcholine in pharmaceutical formulations and industrial equipment cleaning rinse water using the enzyme glycerophosphocholine phosphodiesterase and the WAKO Phospholipids C assay kit was proposed. The method is based on the enzymatic hydrolysis of α -GPC to choline by glycerophosphocholine phosphodiesterase, the reaction of choline with the components of the assay kit, and the colourimetric determination of the formed product. The calibration graph is linear in the range from 1 to 40 mg/l of α -GPC, the molar attenuation coefficient is 1,110 m²/mol, the limit of detection is 1 mg/l, the limit of quantification is 3.3 mg/l, the method is selective with respect to the common excipients, shows a good accuracy (the relative uncertainty does not exceed 7%) and precision (the relative standard deviation does not exceed 5.5%), does not require lengthy sample preparation and sophisticated laboratory equipment and is suitable for the routine analysis of pharmaceutical formulations and industrial equipment cleaning rinse water.

Submitted 28 October 2021

Accepted 6 April 2023

Published 2 June 2023

Corresponding author
Pavel Anatolyevich Nikolaychuk,
npa@csu.ru

Academic editor
Debabrata Goswami

Additional Information and
Declarations can be found on
page 20

DOI 10.7717/peerj-achem.24

© Copyright
2023 Nikolaychuk

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects UV-Visible Spectroscopy

Keywords L- α -glycerylphosphorylcholine, Spectrophotometric determination

INTRODUCTION

L- α -glycerylphosphorylcholine (CAS registry number 28319-77-9, other names: (R)-2,3-dihydroxypropyl(2-(trimethylammonio)ethyl)phosphate, α -GPC, *sn*-glycero-3-phosphocholine, choline alfoscerate) is a water-soluble natural compound found in the human brain and a precursor to acetylcholine (Choi, Hwang & Shin, 2020; Colucci et al., 2012; Lee, Young Choi & Won Suh, 2018; Moreno, 2003; Kidd, 2004). It is used for the treatment of Alzheimer's disease (Moreno, 2003; Hwang & Park, 2019; Selezneva, Kolykhalov & Gavrilova, 2020; Kim et al., 2017; Lanctôt et al., 2017), other dementias and cognitive impairment (Lee et al., 2017; Colucci et al., 2012; Doggrell & Evans, 2003; Sangiorgi et al., 1994; Putilina, 2020), dry eye syndrome (Choi, Hwang & Shin, 2020), and as the

nootropic agent (Colucci *et al.*, 2012; Traini, Bramanti & Amenta, 2013; Tamura *et al.*, 2021; Nobis & Husain, 2018). It also could increase a physical performance (Bellar, LeBlanc & Campbell, 2015; Marcus *et al.*, 2017; Bogolepova *et al.*, 2021), could enhance the growth hormone secretion (Kawamura *et al.*, 2012), and could be a possible cancer biomarker (Jia *et al.*, 2016; Moestue *et al.*, 2012; Smith *et al.*, 2017). α -GPC is a non-prescription drug in many countries (Kim & Cho, 2019), and is manufactured in large quantities (Van Hoogevest & Wendel, 2014). *e.g.*, the Russian State Register of Pharmaceutical Products (<https://grls.rosminzdrav.ru/Default.aspx>) contains more than 30 different medications containing α -GPC including oral solutions, intravenous injections and capsules.

Cleaning of pharmaceutical equipment and determination of the product residues in the cleaning rinse water and on the manufacturing equipment surface is the important step in the pharmaceutical production (Prabu & Suriyaprakash, 2010; Agalloco, 1992; Nassani, 2005). Both European and US Pharmacopoeias do not contain monographs on α -GPC and do not propose methods for its assay, whereas the *State Pharmacopoeia of the Russian Federation (14th Edition) (2018)* proposes a method utilising the non-aqueous acid–base titration using crystal violet for end-point detection. However, this titration method is not suitable for quantification of microgram amounts of a substance in an aqueous solution (Fritz, 1950; Riddick, 1958). There are currently different analytical approaches available for the determination of various choline compounds (Phillips, 2012; Wilson & Lorenz, 1979), including NMR-spectrometry (Holmes, Snodgrass & Iles, 2000), liquid (Zeisel *et al.*, 2003; Andrieux *et al.*, 2008), gas (Garavelli, 1972) and ion-exchange chromatography (Dorsey, Hansen & Gilbert, 1980; Laikhtman & Rohrer, 1999), capillary electrophoresis (Carter & Trenerry, 1996), electrochemical methods (Panfili *et al.*, 2000; Pati *et al.*, 2005) and colourimetry. However, only a few of these methods were adopted specifically for the quantification of α -GPC. Holmes, Snodgrass & Iles (2000) developed a NMR-method for the determination of various choline compounds including α -GPC in milk after extraction. Pomfret, Schurman & Zeisel (1989) utilised preparative high-pressure liquid chromatography followed by gas chromatography with mass-spectrometric detection for analysis of different choline derivatives in human tissues. Later, Holmes-McNary *et al.* (1996) used the same method for determination of choline compounds in milk. Another liquid chromatographic method with mass-spectrometric detection for the determination of different choline compounds in tissues and foods was proposed by Koc *et al.* (2002), and later modified by Likes *et al.* (2007). Later, another modification of this method was proposed by Zhao, Xiong & Curtis (2011). Kozitsyna (2017) described a liquid chromatographic determination of α -GPC in pharmaceutical formulations with refractometric detection. Another liquid chromatographic method with refractometric detection was proposed by Zhao *et al.* (2020). Gavrilin *et al.* (2012) determined α -GPC in pharmaceutical formulations using capillary electrophoresis with indirect UV detection.

The analytical performance of these methods is compared in Table 1. As might be seen, the proposed methods utilising NMR, GC/MS and HPLC/MS are laborious, require time-consuming sample preparation and advanced instrumentation. The HPLC/refractometric and CE/UV methods are simple and quick, but lack both selectivity and sensitivity and are unsuitable for the determination of microgram amounts of α -GPC in cleaning rinse

water. The method of determination of trace amounts of pharmaceutical ingredients in the cleaning rinse water should be as rapid and simple as possible; therefore, spectrophotometric determination is a good choice. Although no spectrophotometric method designed especially for α -GPC was reported, there are four well-known groups of methods for free and total choline, and for various choline esters. The first group of methods is based on the precipitation of choline with ammonium diamminetetraakis (thiocyanato-N)chromate (Reinecke's salt), redissolution of the precipitate, and subsequent photometric determination of the coloured solution (Kapfhammer & Bischoff, 1930; Beattie, 1936; Thornton & Broome, 1942; Engel, 1942; Glick, 1944; Marenzi & Cardini, 1943; Bandelin & Tuschhoff, 1951). The second group of methods implements the precipitation of choline with potassium triiodide, and either the determination of liberated iodine (Staněk, 1905; Sharpe, 1923; Hayashi, Unemoto & Miyaki, 1962), or the redissolution and subsequent photometric determination of choline triiodide (Appleton *et al.*, 1953). The third group of methods is based on the reaction of choline with phosphormolybdic acid (Wheeldon & Collins, 1958; Wachsmuth & Van Koeckhoven, 1959). The fourth group of methods uses enzymatic oxidation of choline by choline oxidase, and the subsequent determination of generated hydrogen peroxide (Rahimi & Joseph, 2019). This might be done by the reaction of hydrogen peroxide with phenol and 4-aminoantipyrine (Woollard & Indyk, 1990), with 3,5-dimethoxy-N-ethyl-N-(2-hydroxy-3-sulfopropyl)-sodium aniline and 4-aminoantipyrine (Maeda *et al.*, 1993; Mine, 1996), with dichlorofluorescein (Khan *et al.*, 1992), with 3,3',5,5'-tetramethylbenzidine in presence of MoS₂ or WS₂ nanoparticles (Nirala, Vinita & Prakash, 2018; Vinita, Nirala & Prakash, 2021), with 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (Nikzad & Karami, 2018), with Fe²⁺ and o-phenylenediamine (Chen *et al.*, 2018). In addition, choline might be estimated colorimetrically with triiodide/activated charcoal/molybdenum blue system (Zimmerman & Ibrahim, 2018), with *cis*-aconitic anhydride (Böttcher, Pries & Van Gent, 1961), or with 25,26,27,28-tetrahydroxycalix[4]arene-5,11,17,23-tetrasulfonic acid sodium salt (Abd El-Rahman *et al.*, 2019).

The methods based on reactions with Reinecke's salt, potassium triiodide and phosphormolybdic acid require lengthy precipitation and redissolution steps and are not suitable for rapid routine analysis. The methods proposed by Böttcher, Pries & Van Gent (1961) and by Abd El-Rahman *et al.* (2019) are simple but employ rare and expensive reagents. On the other hand, enzymatic methods are rapid, simple, and many commercial assay kits utilising these methods are available. These commercial assay kits also contain phospholipases, which allows them to quantify not only the free choline, but also choline-containing phospholipids. The WAKO Phospholipids C assay kit manufactured by Wako Diagnostics (Mountain View, CA, USA) is based on the method of Maeda *et al.* (1993). It contains phospholipase D, which hydrolyses phospholipids to choline, the choline then is oxidised by choline oxidase to betaine and hydrogen peroxide, which reacts with 3,5-dimethoxy-N-ethyl-N-(2-hydroxy-3-sulfopropyl)-sodium aniline and 4-aminoantipyrine in presence of peroxidase and produces a blue pigment that might be determined colourimetrically. α -GPC is not affected by phospholipase D, because it is usually produced from phospholipids by other enzymes (Oyeneye *et al.*, 2020; Hayaishi

Table 1 The comparison of analytical performance of the proposed method with that of the other methods of α -GPC analysis available in the literature.

Method	Reference	Range (mg/l)	Accuracy (%)	Precision (%)	Analysis time
NMR	<i>Holmes, Snodgrass & Iles (2000)</i>	1.3–130	7	Not specified	Sample preparation 1 h + spectrum acquisition 10–15 min
Preparative HPLC + GC/MS	<i>Pomfret, Schurman & Zeisel (1989)</i>	0.5–5000	5	4	Sample preparation 1 h + α -GPC retention time 15 min
HPLC/MS	<i>Koc et al. (2002)</i> and <i>Zhao, Xiong & Curtis (2011)</i>	0.5–5000	12	Not specified	α -GPC retention time 20 min
HPLC/Refractometric	<i>Kozitsyna (2017)</i>	10,000	Not specified	Not specified	α -GPC retention time 4 min
HPLC/Refractometric	<i>Zhao et al. (2020)</i>	80–800	14	2	α -GPC retention time 10 min
CE/UV	<i>Gavrilin et al. (2012)</i>	125,000–375,000	2	1	α -GPC retention time 15 min
Spectrophotometric	This work	3–40	7	5.5	Incubation time 10 min + absorbance measurement

& Kornberg, 1954) like phospholipase A₁ (*Sonkar et al., 2019; Zhang, Liu & Wang, 2012; Bang, Kim & Kim, 2016; Liang et al., 2021*), phospholipase A₂ (*Blasi et al., 2006; Liang et al., 2021*), phospholipase B (*Kim et al., 2020*) and *Rhizopus chinensis* lipase (*Zhang, Wang & Liu, 2012*). However, the hydrolysis of α -GPC to choline might be achieved by the enzyme glycerophosphocholine phosphodiesterase (*Hayaishi & Kornberg, 1954; Sonkar et al., 2019; Oyeneye et al., 2020*). This way, by combining glycerophosphocholine phosphodiesterase with the reagents of the WAKO Phospholipids C assay kit, the quantitative colourimetric measurement of α -GPC becomes possible. The aim of this study is to develop a method of determination of α -GPC in pharmaceutical formulations and industrial equipment cleaning rinse water using the glycerophosphocholine phosphodiesterase and the WAKO Phospholipids C assay kit.

MATERIALS & METHODS

Reagents and equipment

The WAKO Phospholipids C assay kit was purchased from Wako Diagnostics (Mountain View, CA, USA). It consists of the colour reagent containing phospholipase D, choline oxidase, peroxidase, 3,5-dimethoxy-N-ethyl-N-(2-hydroxy-3-sulfopropyl)-sodium aniline and 4-aminoantipyrine and of the buffer solution, which composition and pH value are not specified. Native mold *sn*-glycerol-3-phosphocholine phosphodiesterase, in the form of the lyophilised powder containing tris(hydroxymethyl)aminomethane buffer salt, was purchased from Creative Enzymes (Shirley, NY, USA). The Hydranal moisture test kit for visual Karl-Fisher titration was purchased from Fluka (Buchs, Switzerland). Acetic anhydride (99%), methyl-4-hydroxybenzoate (99%) and propyl-4-hydroxybenzoate (99%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Mercury (II) acetate (analytical grade), potassium hydrogen phthalate (analytical grade), perchloric acid (analytical grade), crystal violet (analytical grade) and glycerol (analytical grade) were purchased from Khimreaktivsnab (Tashkent, Uzbekistan). Glacial acetic acid was purchased from Lenreaktiv (Saint Petersburg, Russia). Choline alfoscerate (98%) was purchased from Lipoid GmbH (Ludwigshafen am Rhein, Germany). Different pharmaceutical formulations containing α -GPC were purchased from Sotex (Moscow, Russia). The flat plates made of stainless steel 12X12H10T were used to model the cleaning of industrial equipment.

The analytical balance Sartorius Cubis MSA 225P-ICE-DI was used for weighting. The various micropipettes manufactured by Thermo Fisher Scientific (Waltham, MA, USA) were used for taking aliquots. The spectrophotometer Mettler Toledo UV7 was used for colorimetric measurements. The water bath Stegler WB-4 was used for sample incubations. The microburette Duran AS 5 ml was used for titration. The chemical glassware of the 2nd grade was used. Water for preparation of solutions was twice distilled and then deionised with Sartorius Arium Pro VF Ultrapure Water system.

Preparation of the colour reagent

The contents of one vial with the colour reagent and one vial with the buffer from the WAKO Phospholipids C assay kit, and the contents of one vial with *sn*-glycerol-3-phosphocholine phosphodiesterase were mixed together. The vials were rinsed with the resulting solution; the rinses were collected into the 50 ml volumetric flask, and the volume of the solution was adjusted by water. The solution was stored in the refrigerator.

Preparation of the 0.5% solution of crystal violet

A total of 0.50 g of crystal violet was weighted, dissolved in glacial acetic acid; the solution was transferred to the 100 ml volumetric flask, and the volume of the solution was adjusted by glacial acetic acid.

Preparation of the 3% solution of mercury (II) acetate

A total of 3.00 g of mercury (II) acetate was weighted, dissolved in glacial acetic acid, the solution was transferred to the 100 ml volumetric flask, and the volume of the solution was adjusted by glacial acetic acid.

Preparation and standardisation of the 0.1 M solution of perchloric acid

A total of 8.5 ml of perchloric acid was dissolved in ca. 900 ml of glacial acetic acid, then 30 ml of acetic anhydride was added, the solution was transferred to the 1,000 ml volumetric flask, and the volume of the solution was adjusted by glacial acetic acid. The water content in the solution was determined by visual Karl-Fisher titration using the Hydranal moisture test kit. If the water content was less than 0.1%, more water was added, and if it was greater than 0.2%, more acetic anhydride was added, and the water content determination was repeated. The solution was allowed to stand for 24 h. To standardise the solution 0.350 g of potassium hydrogen phthalate was weighted, dissolved in glacial acetic acid protected from light, and titrated with the perchloric acid solution using 0.05 ml of the 0.5% solution of crystal violet as indicator. This preparation procedure complies with *State Pharmacopoeia of the Russian Federation (14th Edition) (2018)*.

Preparation of the 100 mg/l stock solution of α -GPC

A total of 1.0000 g of α -GPC was weighted, dissolved in glacial acetic acid, the solution was transferred to the 100 ml volumetric flask and the volume of the solution was adjusted by glacial acetic acid. The exact concentration of the solution was determined by titration. For this the aliquot of 5.0 ml of the prepared solution was transferred to the titration flask, 40 ml of acetic anhydride and 10 ml of the 3% solution of mercury (II) acetate was added, the solution was mixed and titrated with the standardised solution of 0.1 M perchloric

acid using 0.05 ml of the 0.5% solution of crystal violet as indicator. Then the appropriate aliquot of the prepared solution with the determined concentration was taken, transferred to the 1,000 ml volumetric flask, and the volume of the solution was adjusted by water. The stock solution was stored in a refrigerator.

Preparation of working solutions of α -GPC

The working solutions of α -GPC with different concentrations ranging from 1 to 100 mg/l were prepared by appropriate dilution of the stock solution with water. The working solutions were prepared daily.

Preparation of sample solutions from injections

The solutions for intravenous injections available on the Russian local market contain a 250 g/l solution of α -GPC. The contents of ten ampoules from the single package were collected into a beaker; the aliquot of 5.0 ml was taken, transferred to the 500 ml volumetric flask, dissolved in water, and the volume of the solution was adjusted by water. The aliquot of 5.0 ml of the prepared solution was taken, transferred to another 500 ml volumetric flask, and the volume of the solution was adjusted by water. The concentration of α -GPC in the resulting solution equals 25 mg/l.

Preparation of sample solutions from oral solutions

The oral solutions available on the Russian local market contain a 120 g/l solution of α -GPC. The contents of ten ampoules from the single package were collected into a beaker; the aliquot of 5.0 ml was taken, transferred to the 500 ml volumetric flask, dissolved in water, and the volume of the solution was adjusted by water. The aliquot of 5.0 ml of the prepared solution was taken, transferred to another 500 ml volumetric flask, and the volume of the solution was adjusted by water. The concentration of α -GPC in the resulting solution equals 12 mg/l.

Preparation of sample solutions from capsules

The capsules available on the Russian local market contain 400 mg of α -GPC. The contents of ten capsules from the single package were collected into a beaker and dissolved in water; the solution was transferred to the 1,000 ml volumetric flask, dissolved in water, and the volume of the solution was adjusted by water. The aliquot of 5.0 ml of the prepared solution was taken, transferred to the 500 ml volumetric flask, and the volume of the solution was adjusted by water. The concentration of α -GPC in the resulting solution equals 40 mg/l.

Preparation of model rinse water samples from injections

The contents of ten ampoules from the single package were collected into a beaker; the aliquot of 5.0 ml was taken, transferred to the 500 ml volumetric flask, dissolved in water, and the volume of the solution was adjusted by water. The aliquot of 1.0 ml of the prepared solution was taken, placed onto the flat plate made of stainless steel 12X12H10T, and allowed to dry in the fume hood. The plate was rinsed several times with water, the combined rinses were transferred to the 100 ml volumetric flask, and the volume of the solution was adjusted by water. The expected concentration of α -GPC in the model rinse water sample equals 25 mg/l.

Preparation of model rinse water samples from oral solutions

The contents of ten ampoules from the single package were collected into a beaker; the aliquot of 5.0 ml was taken, transferred to the 500 ml volumetric flask, dissolved in water, and the volume of the solution was adjusted by water. The aliquot of 1.0 ml of the prepared solution was taken, placed onto the flat plate made of stainless steel 12X12H10T, and allowed to dry in the fume hood. The plate was rinsed several times with water, the combined rinses were transferred to the 100 ml volumetric flask, and the volume of the solution was adjusted by water. The expected concentration of α -GPC in the model rinse water sample equals 12 mg/l.

Preparation of model rinse water samples from capsules

The contents of ten capsules from the single package were collected into a beaker; the aliquot of 5.0 ml was taken, transferred to the 500 ml volumetric flask, dissolved in water, and the volume of the solution was adjusted by water. The aliquot of 1.0 ml of the prepared solution was taken, placed onto the flat plate made of stainless steel 12X12H10T, and allowed to dry in the fume hood. The plate was rinsed several times with water, the combined rinses were transferred to the 100 ml volumetric flask, and the volume of the solution was adjusted by water. The expected concentration of α -GPC in the model rinse water sample equals 40 mg/l.

General procedure for the determination of α -GPC

A total of 3.0 ml of the colour reagent was mixed with 1.0 ml of working or sample solution of α -GPC in a test tube. The blank solution was prepared by mixing 3.0 ml of the colour reagent with 1.0 ml of water in another test tube. The contents of the test tubes were mixed, placed in the water bath and incubated at the temperature of 37 °C for 10 min. Then the absorbance of the working or sample solution of α -GPC at the wavelength of 595 nm in the glass cuvette with the optical path length one cm was measured against the blank solution.

RESULTS

Selection of the wavelength

The working solutions of α -GPC with the concentration of 30 mg/l and the blank solution were prepared and treated as described in the general procedure, and the spectrum of the working solution was recorded in the wavelength interval from 190 to 1,100 nm with the wavelength step of 0.2 nm in the glass cuvette with the optical path length of one cm against the blank solution. The spectrum is shown in Fig. 1. The maximum absorbance was observed at the wavelength of 595 nm. This wavelength was chosen for all further measurements.

Selection of the sample volume

The working solutions of α -GPC with the concentration of 30 mg/l and the blank solution were prepared as described in the general procedure. In the series of the test tubes, 3.0 ml of the colour reagent were mixed with the various volumes of the working solution ranging from 0.2 to 2.0 ml. The corresponding blank solutions were prepared in another series




Figure 1 The visible spectrum of the coloured product of the enzymatic oxidation of α -GPC. A solid curve represents the visible spectrum of the coloured product of the working solutions of α -GPC with the concentration of 30 mg/l that was recorded in the wavelength interval from 190 to 1,100 nm with the wavelength step of 0.2 nm in the glass cuvette with the optical path length of one cm against the blank solution. A dashed line outlines the maximum absorbance wavelength of 595 nm.

Full-size  DOI: 10.7717/peerj.chem.24/fig-1

Table 2 The dependence of the absorbance of the coloured product on the sample volume.

Sample volume (ml)	Absorbance at 595 nm
0.2	0.265
0.4	0.509
0.6	0.693
0.8	0.971
1.0	1.276
1.5	1.141
2.0	1.016

of test tubes by mixing 3.0 ml of the colour reagent with the various volumes of water. The solutions were incubated in the water bath at 37 °C for 10 min. The absorbances of prepared solutions with the different sample volume at the wavelength of 595 nm in the glass cuvette with the optical path length one cm were measured against the corresponding blank solutions. The results are shown in Table 2 and in Fig. 2. With the increase of the sample volume the molar concentration of α -GPC also increases, which favours the reaction rate to increase, but at the same point the molar concentrations of assay kit reagents and enzymes decrease by dilution, which favours the reaction rate to decrease. Therefore, at some point the reaction rate and the absorbance of the coloured product reach their maxima. The maximum absorbance was observed at the sample volume of 1 ml. This sample volume was chosen for all further measurements.





Figure 2 The dependence of the absorbance of the coloured reaction product on the sample volume.

Full-size  DOI: [10.7717/peerj.chem.24/fig-2](https://doi.org/10.7717/peerj.chem.24/fig-2)

Selection of the incubation time



The working solutions of α -GPC with the concentration of 30 mg/l and the blank solution were prepared as described in the general procedure. In the series of the test tubes, 3.0 ml of the colour reagent were mixed with 1.0 ml of working solution. The blank solution was prepared by mixing 3.0 ml of the colour reagent with 1.0 ml of water in another test tube. The solutions were incubated in the water bath at 37 °C for the various time intervals ranging from 1 to 20 min. The absorbances of prepared solutions with the different incubation time at the wavelength of 595 nm in the glass cuvette with the optical path length one cm were measured against the blank solution. The results are shown in Table 3 and in Fig. 3. As one might see from Fig. 3, after 10 min the overall reaction becomes very slow, and the further absorbance increase becomes asymptotic, which makes it pointless to wait for longer. In contrast, taking a lesser period of time decreases the absorbance significantly and this reduces the sensitivity. The optimal absorbance was observed at the incubation time of 10 min. This incubation time was chosen for all further measurements.

Construction of the calibration curve

The working solutions of α -GPC with different concentrations ranging from 1 to 80 mg/l and the blank solution were prepared as described in the general procedure. In the series of the test tubes, 3.0 ml of the colour reagent were mixed with 1.0 ml of stock solution and prepared working solutions. The blank solution was prepared by mixing 3.0 ml of the colour reagent with 1.0 ml of water in another test tube. The solutions were incubated in the water bath at 37 °C for 10 min. The absorbances of prepared solutions with the different concentration of α -GPC at the wavelength of 595 nm in the glass cuvette with the optical path length one cm were measured against the blank solution. The results are shown in Table 4 and Fig. 4.

Table 3 The dependence of the absorbance of the coloured product on the incubation time.

Incubation time (min)	Absorbance at 595 nm
1.0	0.263
2.0	0.481
3.0	0.656
4.0	0.803
6.0	1.025
8.0	1.176
10.0	1.282
15.0	1.355
20.0	1.406

**Figure 3** The dependence of the absorbance of the coloured reaction product on the incubation time.Full-size  DOI: [10.7717/peerj.chem.24/fig-3](https://doi.org/10.7717/peerj.chem.24/fig-3)

Analytical performance



The analytical performance of the method was determined in accordance with *State Pharmacopoeia of the Russian Federation (14th Edition) (2018)* guidelines. The method was tested for linearity, limits of detection and quantification, selectivity, accuracy, and inter- and intra-day precision.

Linearity

According to Fig. 2, the dependence of the absorbance of the coloured product at 595 nm on the concentration of α -GPC is linear in the range from 1 to 40 mg/l. The regression analysis was performed using the least-squares technique (*Adrain, 1808*). Additionally, the Ringbom's optimum range (*Ringbom, 1938; Ayres, 1949; Youmans & Brown, 1976*), the molar attenuation coefficient, and the Sandell's sensitivity coefficient (*Sandell, 1944*) were calculated. The parameters of the regression equation are listed in Table 5.

Table 4 The dependence of the absorbance of the coloured product on the concentration of α -GPC.

Concentration of α -GPC (mg/l)	Absorbance at 595 nm
1	0.029
2	0.061
4	0.158
5	0.221
10	0.447
15	0.618
20	0.844
30	1.288
40	1.710
60	2.447
80	2.790
100	2.931

**Figure 4** The dependence of the absorbance of the coloured reaction product on the concentration of α -GPC. Empty circles represent the data points, and a dashed line corresponds to the regression equation.Full-size  DOI: 10.7717/peerj.chem.24/fig-4

Limit of detection and limit of quantification

The limit of detection and the limit of quantification of the method were calculated according to *Currie (1999)*, *Shrivastava & Gupta (2011)* and *Little (2015)*. The values are presented in [Table 5](#).

Selectivity with respect to common excipients

According to the Russian State Register of Pharmaceutical Products (<https://grls.rosminzdrav.ru/Default.aspx>), intravenous injections contain only a solution of α -GPC

Table 5 The parameters of the linear regression of the dependence of the absorbance of the coloured product on the concentration of α -GPC, and the analytical parameters of the method.

Parameter	Value
Slope and its confidence interval ($f = 7, p = 95\%$) (l/mg)	0.0431 ± 0.0004
Intercept and its confidence interval ($f = 7, p = 95\%$)	-0.010 ± 0.008
R ² value	0.9994
Linearity range (mg/l)	1–40
Ringbom's optimum range (mg/l)	5–16
Molar attenuation coefficient and its confidence interval ($f = 7, p = 95\%$) (m ² /mol)	$1,110 \pm 10$
Sandell's sensitivity coefficient and its confidence interval ($f = 7, p = 95\%$) ($\mu\text{g}/\text{cm}^2$)	0.023 ± 0.009
Limit of detection (mg/l)	1.0
Limit of quantification (mg/l)	3.3

without excipients, oral solutions contain methyl-4-hydroxybenzoate and propyl-4-hydroxybenzoate, and capsules contain glycerol as the common excipients. The possible interference of these excipients as well as of acetic acid (because it was used in the stock solution preparation) was studied. For that, the 50 mg/l solutions of methyl-4-hydroxybenzoate and propyl-4-hydroxybenzoate, and the 1% solutions of glycerol and acetic acid were prepared. 3.0 ml of each solution were placed in the test tubes, 1.0 ml of the colour reagent was added to each one, and the solutions were incubated in the water bath at the temperature 37 °C for 60 min. No colour development was observed; this indicates that the tested excipients did not interfere.

However, the implementation of the WAKO Phospholipids C assay kit for the analysis of α -GPC in complex matrices is not possible. Blood and other bodily fluids contain phospholipids, which are also affected by this kit, and in this case it quantifies the phospholipids instead of α -GPC. Because one of the reaction steps includes the formation of hydrogen peroxide, any other enzymes and substrates that produce H₂O₂ also interfere. This implies that this method is not suitable for the determination of α -GPC in food and plant material, because many of raw natural ingredients contain both glucose and glucose oxidase, which lead to the H₂O₂ production.

Accuracy

Four series of experiments were conducted. In the first series ten working solutions with the concentration of α -GPC equal to 5 mg/l, in the second series ten sample solutions from injections with the concentration of α -GPC equal to 25 mg/l, in the third series ten sample solutions from oral solution with the concentration of α -GPC equal to 12 mg/l, and in the fourth series ten sample solutions from capsules with the concentration of α -GPC equal to 40 mg/l were prepared. The solutions were treated as described in the general procedure, and then the absorbance of the coloured product was recorded; the concentrations of the solutions were calculated according to the regression equation, and the relative uncertainties were determined. The results are collected in Table 6.

Table 6 The accuracy test of the method.

	Sample number	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Relative uncertainty, %
Experiment 1: Working solution, 5 mg/l	1	0.198	4.83	3.47
	2	0.205	4.98	0.46
	3	0.213	5.16	3.27
	4	0.196	4.78	4.41
	5	0.205	4.99	0.20
	6	0.215	5.22	4.46
	7	0.209	5.08	1.50
	8	0.207	5.03	0.63
	9	0.210	5.10	2.07
	10	0.203	4.94	1.25
	Mean value	0.207	5.01	2.17
Experiment 2: Solution from intravenous injection, 25 mg/l	1	1.077	25.23	0.93
	2	1.076	25.21	0.83
	3	1.069	25.04	0.17
	4	1.059	24.81	0.76
	5	1.060	24.82	0.73
	6	1.061	24.85	0.59
	7	1.063	24.89	0.44
	8	1.077	25.21	0.84
	9	1.062	24.88	0.50
	10	1.067	25.00	0.01
	Mean value	1.067	24.99	0.58
Experiment 3: Solution from oral solution, 12 mg/l	1	0.501	11.85	1.26
	2	0.500	11.84	1.37
	3	0.503	11.90	0.81
	4	0.515	12.17	1.43
	5	0.498	11.79	1.79
	6	0.502	11.89	0.95
	7	0.512	12.11	0.92
	8	0.498	11.79	1.75
	9	0.498	11.80	1.69
	10	0.498	11.78	1.85
	Mean value	0.502	11.89	1.38

(continued on next page)

Table 6 (continued)

	Sample number	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Relative uncertainty, %
	1	1.704	39.77	0.57
	2	1.710	39.90	0.25
	3	1.723	40.20	0.50
	4	1.709	39.88	0.29
Experiment 4: Solution from capsules, 40 mg/l	5	1.718	40.10	0.24
	6	1.716	40.05	0.11
	7	1.708	39.86	0.35
	8	1.719	40.12	0.30
	9	1.722	40.20	0.49
	10	1.712	39.95	0.13
	Mean value	1.714	40.00	0.32

Intra-day precision

Four series of experiments were conducted. In the first series ten working solutions with the concentration of α -GPC equal to 5 mg/l, in the second series ten sample solutions from injections with the concentration of α -GPC equal to 25 mg/l, in the third series ten sample solutions from oral solution with the concentration of α -GPC equal to 12 mg/l, and in the fourth series ten sample solutions from capsules with the concentration of α -GPC equal to 40 mg/l were prepared. The solutions were treated as described in the general procedure, and then the absorbance of the coloured product was recorded; the concentrations of the solutions were calculated according to the regression equation, and the relative standard deviations were determined. The results are collected in Table 7.

Inter-day precision

Four series of experiments were conducted. In the first series a working solution with the concentration of α -GPC equal to 5 mg/l, in the second series a sample solution from injections with the concentration of α -GPC equal to 25 mg/l, in the third series a sample solution from oral solution with the concentration of α -GPC equal to 12 mg/l, and in the fourth series a sample solution from capsules with the concentration of α -GPC equal to 40 mg/l were prepared each day during consecutive five days. The solutions were treated as described in the general procedure, and then the absorbance of the coloured product was recorded; the concentrations of the solutions were calculated according to the regression equation, and the relative standard deviations were determined. The results are collected in Table 8.

Accuracy for the determination of model rinse water samples

Three series of experiments were conducted. In the first series five model rinse water samples from injections with the concentration of α -GPC equal to 25 mg/l, in the second series five model rinse water solutions from oral solution with the concentration of α -GPC equal to 12 mg/l, and in the third series five model rinse water solutions from capsules with the concentration of α -GPC equal to 40 mg/l were prepared. The solutions were treated as described in the general procedure, and then the absorbance of the coloured

Table 7 The intra-day precision test of the method.

Sample number	Experiment 1: Working solution, 5 mg/l		Experiment 2: Solution from intravenous injection, 25 mg/l		Experiment 3: Solution from oral solution, 12 mg/l		Experiment 4: Solution from capsules, 40 mg/l	
	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Absorbance at 595 nm	Concentration of α -GPC (mg/l)
1	0.208	5.06	1.073	25.12	0.498	11.79	1.714	40.00
2	0.210	5.11	1.059	24.81	0.513	12.13	1.707	39.84
3	0.213	5.18	1.073	25.12	0.517	12.22	1.719	40.13
4	0.202	4.93	1.058	24.79	0.516	12.21	1.708	39.86
5	0.211	5.13	1.058	24.77	0.498	11.78	1.721	40.16
6	0.203	4.94	1.060	24.83	0.514	12.17	1.721	40.15
7	0.210	5.10	1.075	25.18	0.504	11.94	1.704	39.78
8	0.207	5.05	1.058	24.79	0.509	12.04	1.707	39.84
9	0.200	4.86	1.073	25.12	0.511	12.09	1.713	39.97
10	0.214	5.21	1.058	24.79	0.499	11.81	1.716	40.04
Mean value	0.208	5.06	1.065	24.93	0.508	12.02	1.713	39.98
SD	0.005	0.114	0.008	0.177	0.008	0.176	0.006	0.141
RSD (%)	2.36	2.25	0.72	0.71	1.49	1.46	0.36	0.35

Table 8 The inter-day precision test of the method.

Sample number	Experiment 1: Working solution, 5 mg/l		Experiment 2: Solution from intravenous injection, 25 mg/l		Experiment 3: Solution from oral solution, 12 mg/l		Experiment 4: Solution from capsules, 40 mg/l	
	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Absorbance at 595 nm	Concentration of α -GPC (mg/l)
1	0.205	4.99	1.058	24.78	0.514	12.15	1.717	40.06
2	0.197	4.80	1.059	24.81	0.502	11.89	1.705	39.80
3	0.214	5.20	1.078	25.23	0.530	12.53	1.730	40.37
4	0.202	4.91	1.058	24.78	0.505	11.95	1.708	39.85
5	0.210	5.09	1.091	25.55	0.501	11.85	1.736	40.52
Mean value	0.205	4.99	1.069	25.03	0.510	12.07	1.719	40.12
SD	0.007	0.155	0.015	0.348	0.012	0.279	0.014	0.317
RSD (%)	3.25	3.10	1.40	1.39	2.36	2.31	0.79	0.79

Table 9 The accuracy test for the model rinse water solutions.

	Sample number	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Relative uncertainty, %
Experiment 1: Solution from intravenous injection, 25 mg/l	1	1.007	23.60	5.60
	2	0.995	23.31	6.75
	3	0.996	23.33	6.67
	4	1.003	23.51	5.95
	5	1.000	23.43	6.29
	Mean value	1.000	23.44	6.25
Experiment 2: Solution from oral solution, 12 mg/l	1	0.481	11.40	4.98
	2	0.483	11.43	4.71
	3	0.474	11.24	6.37
	4	0.475	11.26	6.14
	5	0.472	11.19	6.76
	Mean value	0.477	11.30	5.79
Experiment 3: Solution from capsules, 40 mg/l	1	1.611	37.60	5.99
	2	1.607	37.52	6.19
	3	1.609	37.56	6.11
	4	1.607	37.52	6.19
	5	1.614	37.67	5.81
	Mean value	1.610	37.58	6.06

product was recorded; the concentrations of the solutions were calculated according to the regression equation, and the relative uncertainties were determined. The results are collected in Table 9.

Precision for the determination of model rinse water samples

Three series of experiments were conducted. In the first series five model rinse water samples from injections with the concentration of α -GPC equal to 25 mg/l, in the second series five model rinse water samples from oral solution with the concentration of α -GPC equal to 12 mg/l, and in the third series five model rinse water sample solutions from

capsules with the concentration of α -GPC equal to 40 mg/l were prepared. The solutions were treated as described in the general procedure, and then the absorbance of the coloured product was recorded; the concentrations of the solutions were calculated according to the regression equation, and the relative standard deviations were determined. The results are collected in Table 10.

Comparison of the results of titrimetric and spectrophotometric determinations

A total of 1.0000 g of α -GPC was weighted, dissolved in ca. 80 ml of glacial acetic acid, the solution was transferred to the 100 ml volumetric flask and the volume of the solution was adjusted by glacial acetic acid. Ten aliquots of 5.0 ml of the prepared solution were transferred to the titration flasks, 40 ml of acetic anhydride and 10 ml of the 3% solution of mercury (II) acetate was added to the each, the solutions were mixed and titrated with the standardised solution of 0.1 M perchloric acid using 0.05 ml of the 0.5% solution of crystal violet as indicator. Then ten aliquots of 5.0 ml of the prepared solution were taken, transferred to ten 2,000 ml volumetric flasks, and the volumes of the solutions were adjusted by water. The diluted solutions were treated as described in the general procedure, and then the absorbance of the coloured product was recorded, and the concentrations were calculated according to the regression equation. The content of α -GPC in the weighting was calculated using the both methods, and the F-test of equality of variances and the *t*-test of equality of means were performed. The results are shown in Table 11. As could be seen, both the calculated F- and t-values do not exceed the critical values for the given degrees of freedom and *p*-value, which means that these titrimetric and spectrophotometric methods give statistically equal results for the tested sample.

DISCUSSION

The experiments show that the proposed spectrophotometric method is suitable for the determination of α -GPC both in pharmaceutical formulations and in industrial equipment cleaning rinse water. The method is simple; it does not require complicated sample preparation or sophisticated equipment. The method is selective with respect to the common excipients; however, different choline derivatives and other substrates and enzymes producing hydrogen peroxide might interfere, and the influence of more complex matrices was not studied. The molar attenuation coefficient equals 1,110 m²/mol, the limit of detection equals 1 mg/l, and the limit of quantification equals 3.3 mg/l, the calibration curve is linear in the range from 1 to 40 mg/l of α -GPC with the good correlation coefficient, and the optimum range of α -GPC concentrations for determination is 5–16 mg/l. Therefore, this method is less sensitive than more comprehensive NMR, GC/MC and HPLC/MS methods, but more sensitive than HPLC/refractometric and CE/UV methods developed for determination of α -GPC in pharmaceutical formulations. The relative uncertainty for the analysis of pharmaceutical formulations does not exceed 2.5%, which is a fair value for the kinetic method; the relative uncertainty for the analysis of modelling industrial rinse water does not exceed 7%, which is also acceptable for cleaning validation sample analysis. The relative standard deviation does not exceed 2.5% for intra-, 3.5% for

Table 10 The precision test for the model rinse water sample solutions.

Sample number	Experiment 1: Solution from intravenous injection, 25 mg/l		Experiment 2: Solution from oral solution, 12 mg/l		Experiment 3: Solution from capsules, 40 mg/l	
	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Absorbance at 595 nm	Concentration of α -GPC (mg/l)	Absorbance at 595 nm	Concentration of α -GPC (mg/l)
1	1.036	24.26	0.496	11.74	1.622	37.86
2	0.954	22.36	0.516	12.19	1.600	37.35
3	1.028	24.08	0.463	10.96	1.531	35.75
4	0.991	23.23	0.482	11.42	1.618	37.78
5	1.027	24.07	0.456	10.80	1.569	36.63
Mean value	1.007	23.59	0.482	11.42	1.588	37.07
SD	0.035	0.801	0.025	0.569	0.038	0.885
RSD (%)	3.43	3.39	5.08	4.98	2.40	2.39

Table 11 The comparison of titrimetric and spectrophotometric methods.

Sample number	Titrimetric method			Spectrophotometric method		
	Volume of the titrant (ml)	Amount of α -GPC in the aliquot (mg)	Amount of α -GPC in the weighting (mg)	Absorbance at 595 nm	Concentration of α -GPC in the aliquot (mg/l)	Amount of α -GPC in the weighting (mg)
1	1.96	50.42	1008.4	1,058	24,77	990,8
2	1.94	49.90	998.0	1,062	24,87	994,8
3	1.9	48.87	977.4	1,074	25,14	1005,6
4	1.94	49.90	998.0	1,066	24,98	999,2
5	1.92	49.39	987.8	1,072	25,11	1004,4
6	1.96	50.42	1008.4	1,058	24,78	991,2
7	1.92	49.39	987.8	1,064	24,93	997,2
8	1.92	49.39	987.8	1,059	24,80	992,0
9	1.92	49.39	987.8	1,061	24,84	993,6
10	1.94	49.90	998.0	1,075	25,17	1006,8
Mean value	1.93	49.70	994.0	1,065	24,94	997,6
Sample variance	0.0004	0.247	98.80	0.00004	0.0236	37.78
F-value ($f_1 = 9, f_2 = 9, p = 95\%$)			2.62	Critical F-value ($f_1 = 9, f_2 = 9, p = 95\%$)		3.18
t-value ($f = 18, p = 95\%$)			0.92	Critical t-value ($f = 18, p = 95\%$)		1.734

inter- day precision, and 5.5% for analysis of modelling industrial rinse water. The accuracy and the precision of the proposed method are comparable with those for other proposed methods and fall within the requirements for the analysis of industrial equipment cleaning validation samples. The analysis revealed no statistical difference between the proposed spectrophotometric method and the non-aqueous titration method of *State Pharmacopoeia of the Russian Federation (14th Edition) (2018)* in the determination of α -GPC in a bulk sample. The proposed method is not intended to compete with the sophisticated NMR, GC/MS and HPLC/MS methods for the analysis of α -GPC and other choline derivatives in complex matrices, but it presents a simple a quick solution when the quantification of residual amounts of α -GPC in an aqueous solution is needed. The method is recommended for the routine and quick analysis of α -GPC in industrial intermediate goods during the intermediate quality control, in pharmaceutical formulations and in industrial equipment cleaning rinse water.

CONCLUSIONS

A simple spectrophotometric method for the determination of α -GPC in pharmaceutical formulations and industrial equipment cleaning rinse water using the enzyme glycerophosphocholine phosphodiesterase and the WAKO Phospholipids C assay kit was proposed. The method is based on the enzymatic hydrolysis of α -GPC to choline, the enzymatic oxidation of choline, the reaction of formed hydrogen peroxide with 3,5-dimethoxy-N-ethyl-N- (2-hydroxy-3-sulfopropyl)-sodium aniline and 4-aminoantipyrine, and the colourimetric determination of the formed product. The method shows good analytical performance, does not require lengthy sample preparation and sophisticated laboratory equipment, and is suitable for routine analysis.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The author received no funding for this work.

Competing Interests

Pavel Anatolyevich Nikolaychuk was employed by LLC “Velpharm” from 10.02.2020 until 30.06.2021.

Author Contributions

- Pavel Anatolyevich Nikolaychuk conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:

The raw data is available in the [Supplemental Files](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj-achem.24#supplemental-information>.

REFERENCES

- Abd El-Rahman MK, Mazzone G, Mahmoud AM, Sicilia E, Shoeib T. 2019.** Spectrophotometric determination of choline in pharmaceutical formulations via host-guest complexation with a biomimetic calixarene receptor. *Microchemical Journal* **146**:735–741 DOI 10.1016/j.microc.2019.01.046.
- Adrain R. 1808.** Research concerning the probabilities of the errors which happen in making observations, &c. *The Analyst; Or Mathematical Museum* **1**(4):93–109.
- Agalloco J. 1992.** “Points to Consider” in the Validation of Equipment Cleaning Procedures. *Journal of Parenteral Science and Technology* **46**(5):163–168.
- Andrieux P, Kilinc T, Perrin C, Campos-Giménez E. 2008.** Simultaneous determination of free carnitine and total choline by liquid chromatography/mass spectrometry in infant formula and health-care products: single-laboratory validation. *Journal of AOAC International* **91**(4):777–785 DOI 10.1093/jaoac/91.4.777.
- Appleton HD, La Du BN, Levy BB, Steele JM, Brodie BB. 1953.** A chemical method for the determination of free choline in plasma. *Journal of Biological Chemistry* **205**(2):803–813 DOI 10.1016/S0021-9258(18)49224-1.
- Ayres GH. 1949.** Evaluation of accuracy in photometric analysis. *Analytical Chemistry* **21**(6):652–657 DOI 10.1021/ac60030a002.
- Bandelin FJ, Tuschhoff JV. 1951.** The determination of choline in the presence of B complex vitamins. *Journal of the American Pharmaceutical Association* **40**(5):245–248 DOI 10.1002/jps.3030400508.
- Bang HJ, Kim IH, Kim BH. 2016.** Phospholipase A₁-catalyzed hydrolysis of soy phosphatidylcholine to prepare l- α -glycerylphosphorylcholine in organic-aqueous media. *Food Chemistry* **190**:201–206 DOI 10.1016/j.foodchem.2015.05.093.
- Beattie FJR. 1936.** A colorimetric method for the determination of choline and acetylcholine in small amounts. *Biochemical Journal* **30**(9):1554–1559 DOI 10.1042/bj0301554.
- Bellar D, LeBlanc NR, Campbell B. 2015.** The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. *Journal of the International Society of Sports Nutrition* **12**(1):1–6 DOI 10.1186/s12970-014-0062-7.
- Blasi F, Cossignani L, Simonetti MS, Brutti M, Ventura F, Damiani P. 2006.** Enzymatic deacylation of l, 2-diacyl-sn-glycero-3-phosphocholines to sn-glycerol-3-phosphocholine. *Enzyme and Microbial Technology* **39**(7):1405–1408 DOI 10.1016/j.enzmictec.2006.03.026.
- Bogolepova AN, Osinovskaya NA, Kovalenko EA, Makhnovich EV. 2021.** Vozmozhnye podhody k terapii astenicheskikh i kognitivnyh narushenij pri postkovidnom sindrome. *Nevrologiya, nejropsihiatriya, psihosomatika* **13**(4):88–93 (In Russian) DOI 10.14412/2074-2711-2021-4-88-93.

- Böttcher CJF, Pries C, Van Gent CM. 1961.** A rapid and sensitive colorimetric microdetermination of free and bound choline. *Recueil Des Travaux Chimiques Des Pays-Bas* **80(11)**:1169–1178 DOI [10.1002/recl.19610801102](https://doi.org/10.1002/recl.19610801102).
- Carter N, Trenerry VC. 1996.** The determination of choline in vitamin preparations, infant formula and selected foods by capillary zone electrophoresis with indirect ultraviolet detection. *Electrophoresis* **17(10)**:1622–1626 DOI [10.1002/elps.1150171023](https://doi.org/10.1002/elps.1150171023).
- Chen H, Lu Q, He K, Liu M, Zhang Y, Yao S. 2018.** A cyclic signal amplification strategy to fluorescence and colorimetric dual-readout assay for the detection of H₂O₂-related analytes and application to colorimetric logic gate. *Sensors and Actuators B: Chemical* **260**:908–917 DOI [10.1016/j.snb.2018.01.085](https://doi.org/10.1016/j.snb.2018.01.085).
- Choi JJ, Hwang JS, Shin YJ. 2020.** Effect of oral choline alfoscerate on patients with keratoconjunctivitis sicca. *Nutrients* **12(5)**:1526 DOI [10.3390/nu12051526](https://doi.org/10.3390/nu12051526).
- Colucci L, Bosco M, Ziello AR, Rea R, Amenta F, Fasanaro AM. 2012.** Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review. *Journal of Experimental Pharmacology* **4**:163–172 DOI [10.2147/JEP.S35326](https://doi.org/10.2147/JEP.S35326).
- Currie LA. 1999.** Detection and quantification limits: origins and historical overview. *Analytica Chimica Acta* **391(2)**:127–134 DOI [10.1016/S0003-2670\(99\)00105-1](https://doi.org/10.1016/S0003-2670(99)00105-1).
- Doggrell SA, Evans S. 2003.** Treatment of dementia with neurotransmission modulation. *Expert Opinion on Investigational Drugs* **12(10)**:1633–1654 DOI [10.1517/13543784.12.10.1633](https://doi.org/10.1517/13543784.12.10.1633).
- Dorsey JG, Hansen LC, Gilbert TW. 1980.** Determination of choline in soybean meal by liquid chromatography with the ion-exchange membrane detector. *Journal of Agricultural and Food Chemistry* **28(1)**:28–32 DOI [10.1021/jf60227a027](https://doi.org/10.1021/jf60227a027).
- Engel RW. 1942.** Modified methods for the chemical and biological determination of choline. *Journal of Biological Chemistry* **144**:701–710 DOI [10.1016/S0021-9258\(18\)72495-2](https://doi.org/10.1016/S0021-9258(18)72495-2).
- Fritz JS. 1950.** Titration of bases in nonaqueous solvents. *Analytical Chemistry* **22(8)**:1028–1029 DOI [10.1021/ac60044a017](https://doi.org/10.1021/ac60044a017).
- Garavelli CB. 1972.** Gas chromatography of choline in high potency multiple vitamin tablets and liver concentrates. *Journal of the Association of Official Analytical Chemists* **55(6)**:1199–1201 DOI [10.1093/jaoac/55.6.1199](https://doi.org/10.1093/jaoac/55.6.1199).
- Gavrilin MV, Mudretsova Yu V, Senchenko SV, Rozhnova SA. 2012.** Razrabotka metodiki kolichestvennogo opredelenija holina al'foscerata i mel'donija metodom kapilljarnogo jelektroforeza. *Voprosy Biologicheskoi, Meditsinskoi I Farmatsevticheskoi Khimii* **4**:12–17 (In Russian).
- Glick D. 1944.** Concerning the reineckate method for the determination of choline. *Journal of Biological Chemistry* **156(2)**:643–652 DOI [10.1016/S0021-9258\(18\)51147-9](https://doi.org/10.1016/S0021-9258(18)51147-9).
- Hayaishi O, Kornberg A. 1954.** Metabolism of phospholipides by bacterial enzymes. *Journal of Biological Chemistry* **206(2)**:647–663 DOI [10.1016/S0021-9258\(19\)50833-X](https://doi.org/10.1016/S0021-9258(19)50833-X).
- Hayashi M, Unemoto T, Miyaki K. 1962.** Improvement on the colorimetric determination of choline with iodine. *Chemical and Pharmaceutical Bulletin* **10(6)**:533–535 DOI [10.1248/cpb.10.533](https://doi.org/10.1248/cpb.10.533).

- Holmes HC, Snodgrass GJAI, Iles RA. 2000.** Changes in the choline content of human breast milk in the first 3 weeks after birth. *European Journal of Pediatrics* **159**(3):198–204 DOI [10.1007/s004310050050](https://doi.org/10.1007/s004310050050).
- Holmes-McNary MQ, Cheng WL, Mar MH, Fussell S, Zeisel SH. 1996.** Choline and choline esters in human and rat milk and in infant formulas. *The American Journal of Clinical Nutrition* **64**(4):572–576 DOI [10.1093/ajcn/64.4.572](https://doi.org/10.1093/ajcn/64.4.572).
- Hwang SG, Park H. 2019.** An analysis on prescribing patterns of Alzheimer's dementia treatment and choline alfoscerate using HIRA claims data. *Korean Journal of Clinical Pharmacy* **29**(1):1–8 DOI [10.24304/kjcp.2019.29.1.1](https://doi.org/10.24304/kjcp.2019.29.1.1).
- Jia M, Andreassen T, Jensen L, Bathen TF, Sinha I, Gao H, Zhao C, Haldosen L-A, Cao Y, Girnita L, Moestue SA, Dahlman-Wright K. 2016.** Estrogen receptor α promotes breast cancer by reprogramming choline metabolism. *Cancer Research* **76**(19):5634–5646 DOI [10.1158/0008-5472.CAN-15-2910](https://doi.org/10.1158/0008-5472.CAN-15-2910).
- Kapfhammer J, Bischoff C. 1930.** Acetylcholin und Cholin aus tierischen Organen. 1. Mitteilung. Darstellung aus Rinderblut. *Hoppe-Seyler's Zeitschrift Für Physiologische Chemie* **191**(3–4):179–182 (In German) DOI [10.1515/bchm2.1930.191.3-4.179](https://doi.org/10.1515/bchm2.1930.191.3-4.179).
- Kawamura T, Okubo T, Sato K, Fujita S, Goto K, Hamaoka T, Iemitsu M. 2012.** Glycerophosphocholine enhances growth hormone secretion and fat oxidation in young adults. *Nutrition* **28**(11–12):1122–1126 DOI [10.1016/j.nut.2012.02.011](https://doi.org/10.1016/j.nut.2012.02.011).
- Khan SM, Khan TM, Wells RD, Maslin DJ, Connock MJ. 1992.** A sensitive enzyme-based colorimetric assay for choline-containing phospholipids. *Journal of the Science of Food and Agriculture* **58**(3):443–445 DOI [10.1002/jsfa.2740580322](https://doi.org/10.1002/jsfa.2740580322).
- Kidd PM. 2004.** GPC (GlyceroPhosphoCholine), ortho-nutraceutical for active living and healthy aging. *Townsend Letter for Doctors and Patients* **249**:96–103.
- Kim H, Cho SW. 2019.** Preparation and evaluation of solid composites containing choline alfoscerate. *Biomedical Science Letters* **25**(2):170–176 DOI [10.15616/BSL.2019.25.2.170](https://doi.org/10.15616/BSL.2019.25.2.170).
- Kim HM, Kang SH, Cho SW, Kang BS. 2017.** Effects of choline alfoscerate and memantine on memory improvement of scopolamine-induced memory impairment animal model of Alzheimer's disease. *Yakhak Hoeji* **61**(6):292–300 DOI [10.17480/psk.2017.61.6.292](https://doi.org/10.17480/psk.2017.61.6.292).
- Kim J, Song Y, Lee SJ, Lee JE, Chung MY, Kim IH, Kim BH. 2020.** Enzymatic preparation of food-grade l- α -glycerylphosphorylcholine from soy phosphatidylcholine or fractionated soy lecithin. *Biotechnology Progress* **36**(1):e2910 DOI [10.1002/btpr.2910](https://doi.org/10.1002/btpr.2910).
- Koc H, Mar MH, Ranasinghe A, Swenberg JA, Zeisel SH. 2002.** Quantitation of choline and its metabolites in tissues and foods by liquid chromatography/electrospray ionization-isotope dilution mass spectrometry. *Analytical Chemistry* **74**(18):4734–4740 DOI [10.1021/ac025624x](https://doi.org/10.1021/ac025624x).
- Kozitsyna OV. 2017.** Development of quality control procedure and study of stability holina alfoscerat solution for intravenous and intra-intensive introduction 250 mg/ml at pjsc biosintez. *Innovatsionnaya Tekhnika I Tekhnologiya* **4**(13):21–24 (In Russian).

- Laikhtman M, Rohrer JS. 1999.** Determination of choline in infant formula by ion chromatography. *Journal of AOAC International* **82**(5):1156–1162
DOI [10.1093/jaoac/82.5.1156](https://doi.org/10.1093/jaoac/82.5.1156).
- Lancôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, Ismail Z, Lyketsos C, Miller DS, Musiek E, Osorio RS, Rosenberg PB, Satlin A, Steffens D, Tariot P, Bain LJ, Carrillo MC, Hendrix JA, Jurgens H, Boot B. 2017.** Neuropsychiatric signs and symptoms of Alzheimer’s disease: new treatment paradigms. *Alzheimer’s Dementia: Translational Research Clinical Interventions* **3**(3):440–449 DOI [10.1016/j.trci.2017.07.001](https://doi.org/10.1016/j.trci.2017.07.001).
- Lee M, Young Choi B, Won Suh S. 2018.** Unexpected effects of acetylcholine precursors on pilocarpine seizure-induced neuronal death. *Current Neuropharmacology* **16**(1):51–58 DOI [10.2174/1570159X15666170518150053](https://doi.org/10.2174/1570159X15666170518150053).
- Lee SH, Choi BY, Kim JH, Kho AR, Sohn M, Song HK, Suh SW. 2017.** Late treatment with choline alfoscerate (1-alpha glycerylphosphorylcholine, α -GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment. *Brain Research* **1654**:66–76
DOI [10.1016/j.brainres.2016.10.011](https://doi.org/10.1016/j.brainres.2016.10.011).
- Liang S, Liu Y, Meng Y, Sun C. 2021.** Two-stage enzymatic hydrolysis of soybean concentrate phospholipid to prepare glycerylphosphorylcholine: optimized by response surface methodology. *Journal of Oleo Science* **70**(2):237–245 DOI [10.5650/jos.ess20261](https://doi.org/10.5650/jos.ess20261).
- Likes R, Madl RL, Zeisel SH, Craig SA. 2007.** The betaine and choline content of a whole wheat flour compared to other mill streams. *Journal of Cereal Science* **46**(1):93–95
DOI [10.1016/j.jcs.2006.11.002](https://doi.org/10.1016/j.jcs.2006.11.002).
- Little TA. 2015.** Method validation essentials, limit of blank, limit of detection, and limit of quantitation. *BioPharm International* **28**(4):48–51.
- Maeda T, Okano C, Miyake A, Sawa J. 1993.** Determination of Choline in Milk and Dairy Products by an Enzymatic Method. *Shokuhin Eiseigaku Zasshi* **34**(1):32–37 (In Japanese) DOI [10.3358/shokueishi.34.32](https://doi.org/10.3358/shokueishi.34.32).
- Marcus L, Soileau J, Judge LW, Bellar D. 2017.** Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. *Journal of the International Society of Sports Nutrition* **14**(1):1–7
DOI [10.1186/s12970-016-0158-3](https://doi.org/10.1186/s12970-016-0158-3).
- Marenzi AD, Cardini CE. 1943.** The colorimetric determination of choline. *Journal of Biological Chemistry* **147**(2):363–370 DOI [10.1016/S0021-9258\(18\)72391-0](https://doi.org/10.1016/S0021-9258(18)72391-0).
- Mine Y. 1996.** Application of the enzymatic methods to the determination of contaminated yolk in egg white. *Food Research International* **29**(1):81–84
DOI [10.1016/0963-9969\(95\)00043-7](https://doi.org/10.1016/0963-9969(95)00043-7).
- Moestue SA, Giskeødegård GF, Cao MD, Bathen TF, Gribbestad IS. 2012.** Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer. *Proceedings of the National Academy of Sciences of the United States of America* **109**(38):E2506
DOI [10.1073/pnas.1208226109](https://doi.org/10.1073/pnas.1208226109).

- Moreno MDJM. 2003.** Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. *Clinical Therapeutics* **25(1)**:178–193 DOI [10.1016/S0149-2918\(03\)90023-3](https://doi.org/10.1016/S0149-2918(03)90023-3).
- Nassani M. 2005.** Cleaning validation in the pharmaceutical industry. *Journal of Validation Technology* **11(4)**:286–298.
- Nikzad N, Karami Z. 2018.** Label-free colorimetric sensor for sensitive detection of choline based on DNAzyme-choline oxidase coupling. *International Journal of Biological Macromolecules* **115**:1241–1248 DOI [10.1016/j.ijbiomac.2018.04.077](https://doi.org/10.1016/j.ijbiomac.2018.04.077).
- Nirala NR, Vinita, Prakash R. 2018.** Quick colorimetric determination of choline in milk and serum based on the use of MoS₂ nanosheets as a highly active enzyme mimetic. *Microchimica Acta* **185(4)**:224 DOI [10.1007/s00604-018-2753-2](https://doi.org/10.1007/s00604-018-2753-2).
- Nobis L, Husain M. 2018.** Apathy in Alzheimer's disease. *Current Opinion in Behavioral Sciences* **22**:7–13 DOI [10.1016/j.cobeha.2017.12.007](https://doi.org/10.1016/j.cobeha.2017.12.007).
- Oyeneye A, Shen J, Shim YY, Tse TJ, Reaney MJ. 2020.** Production of α -glycerylphosphorylcholine and other compounds from wheat fermentation. *ACS Omega* **5(21)**:12486–12494 DOI [10.1021/acsomega.0c01352](https://doi.org/10.1021/acsomega.0c01352).
- Panfil G, Manzi P, Compagnone D, Scarciglia L, Palleschi G. 2000.** Rapid assay of choline in foods using microwave hydrolysis and a choline biosensor. *Journal of Agricultural and Food Chemistry* **48(8)**:3403–3407 DOI [10.1021/jf990803+](https://doi.org/10.1021/jf990803+).
- Pati S, Palmisano F, Quinto M, Zambonin PG. 2005.** Quantitation of major choline fractions in milk and dietary supplements using a phospholipase D bioreactor coupled to a choline amperometric biosensor. *Journal of Agricultural and Food Chemistry* **53(18)**:6974–6979 DOI [10.1021/jf050277o](https://doi.org/10.1021/jf050277o).
- Phillips MM. 2012.** Analytical approaches to determination of total choline in foods and dietary supplements. *Analytical and Bioanalytical Chemistry* **403(8)**:2103–2112 DOI [10.1007/s00216-011-5652-5](https://doi.org/10.1007/s00216-011-5652-5).
- Pomfret EA, Schurman LL, Zeisel SH. 1989.** Measurement of choline and choline metabolite concentrations using high-pressure liquid chromatography and gas chromatography-mass spectrometry. *Analytical Biochemistry* **180(1)**:85–90 DOI [10.1016/0003-2697\(89\)90091-2](https://doi.org/10.1016/0003-2697(89)90091-2).
- Prabu SL, Suriyaprakash TNK. 2010.** Cleaning validation and its importance in pharmaceutical industry. *Pharma Times* **42(7)**:21–25.
- Putilina MV. 2020.** Personificirovannyj vybor preparatov—predshestvennikov holina s pozicij dokazatel'noj mediciny. *Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova* **120(6)**:144–151 (In Russian) DOI [10.17116/jnevro2020120061144](https://doi.org/10.17116/jnevro2020120061144).
- Rahimi P, Joseph Y. 2019.** Enzyme-based biosensors for choline analysis: a review. *TrAC Trends in Analytical Chemistry* **110**:367–374 DOI [10.1016/j.trac.2018.11.035](https://doi.org/10.1016/j.trac.2018.11.035).
- Riddick JA. 1958.** Acid-base titrations in nonaqueous solvents. *Analytical Chemistry* **30(4)**:793–805 DOI [10.1021/ac50163a027](https://doi.org/10.1021/ac50163a027).
- Ringbom A. 1938.** Über die Genauigkeit der colorimetrischen Analysenmethoden I. *Zeitschrift Für Analytische Chemie* **115(9)**:332–343 (In German) DOI [10.1007/BF01753937](https://doi.org/10.1007/BF01753937).

- Sandell EB. 1944.** *Colorimetric determination of traces of metals*. New York: Interscience Publishers.
- Sangiorgi GB, Barbagallo M, Giordano M, Meli M, Panzarasa R. 1994.** α -Glycerophosphocholine in the mental recovery of cerebral ischemic attacks: an Italian multi-center clinical trial. *Annals of the New York Academy of Sciences* **717(1)**:253–269 DOI 10.1111/j.1749-6632.1994.tb12095.x.
- Selezneva ND, Kolykhalov IV, Gavrilova SI. 2020.** Sravnitel'noe prospektivnoe mul'tidisciplinarnoe issledovanie jeffektivnosti holina al'foscerata v profilaktike progressirovanija kognitivnogo deficita u rodstvennikov pacientov s boleznu Al'cgejmera. *Psikhiatriya* **18(1)**:6–15 (In Russian).
- Sharpe JS. 1923.** A method for the quantitative estimation of choline in blood. *Biochemical Journal* **17(1)**:41–42 DOI 10.1042/bj0170041.
- Shrivastava A, Gupta VB. 2011.** Methods for the determination of limit of detection and limit of quantitation of the analytical methods. *Chronicles of Young Scientists* **2(1)**:21–25 DOI 10.4103/2229-5186.79345.
- Smith TA, Phyu SM, Alzyoud KS, Tseng CC. 2017.** Response detection of castrate-resistant prostate cancer to clinically utilised and novel treatments by monitoring phospholipid metabolism. *BioMed Research International* **2017**:4793465 DOI 10.1155/2017/4793465.
- Sonkar K, Ayyappan V, Tressler CM, Adelaja O, Cai R, Cheng M, Glunde K. 2019.** Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. *NMR in Biomedicine* **32(10)**:e4112 DOI 10.1002/nbm.4112.
- Staněk V. 1905.** Über das Cholinperjodid und die quantitative Fällung von Cholin durch Kaliumtrijodid. *Hoppe-Seyler's Zeitschrift Für Physiologische Chemie* **46(3)**:280–285 (In German) DOI 10.1515/bchm2.1905.46.3.280.
- State Pharmacopoeia of the Russian Federation (14th Edition). 2018.** Ministry of Health of the Russian Federation. Available at <https://femb.ru/record/pharmacopeia14>.
- Tamura Y, Takata K, Matsubara K, Kataoka Y. 2021.** Alpha-glycerolphosphorylcholine increases motivation in healthy volunteers: a single-blind, randomized, placebo-controlled human study. *Nutrients* **13(6)**:2091 DOI 10.3390/nu13062091.
- Thornton M, Broome F. 1942.** Determination of choline a photometric modification of Beattie's method. *Industrial & Engineering Chemistry Analytical Edition* **14(1)**:39–41 DOI 10.1021/i560101a014.
- Traini E, Bramanti V, Amenta F. 2013.** Choline alphascerate (alpha-glycerolphosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. *Current Alzheimer Research* **10(10)**:1070–1079 DOI 10.2174/15672050113106660173.
- Van Hoogevest P, Wendel A. 2014.** The use of natural and synthetic phospholipids as pharmaceutical excipients. *European Journal of Lipid Science and Technology* **116(9)**:1088–1107 DOI 10.1002/ejlt.201400219.
- Vinita , Nirala NR, Prakash R. 2021.** Facile and selective colorimetric assay of choline based on AuNPs-WS₂QDs as a peroxidase mimic. *Microchemical Journal* **167**:106312 DOI 10.1016/j.microc.2021.106312.

- Wachsmuth H, Van Koeckhoven L. 1959.** Contribution au dosage de la choline dans le sérum sanguin. *Clinica Chimica Acta* **4(2)**:206–212 (In French)
DOI [10.1016/0009-8981\(59\)90131-7](https://doi.org/10.1016/0009-8981(59)90131-7).
- Wheeldon LW, Collins FD. 1958.** Studies on phospholipids. 3. Determination of choline. *Biochemical Journal* **70(1)**:43–45 DOI [10.1042/bj0700043](https://doi.org/10.1042/bj0700043).
- Wilson J, Lorenz K. 1979.** Biotin and choline in foods—nutritional importance and methods of analysis: a review. *Food Chemistry* **4(2)**:115–129
DOI [10.1016/0308-8146\(79\)90036-0](https://doi.org/10.1016/0308-8146(79)90036-0).
- Woollard DC, Indyk HE. 1990.** The routine, enzymatic estimation of total choline in milk and infant formulas. *Journal of Micronutrient Analysis* **7(1)**:1–14.
- Youmans HL, Brown VH. 1976.** Selection of optimum ranges for photometric analysis. *Analytical Chemistry* **48(8)**:1152–1155 DOI [10.1021/ac50002a022](https://doi.org/10.1021/ac50002a022).
- Zeisel SH, Mar MH, Howe JC, Holden JM. 2003.** Concentrations of choline-containing compounds and betaine in common foods. *The Journal of Nutrition* **133(5)**:1302–1307 DOI [10.1093/jn/133.5.1302](https://doi.org/10.1093/jn/133.5.1302).
- Zhang K, Liu Y, Wang X. 2012.** Enzymatic preparation of L- α -glycerylphosphorylcholine in an aqueous medium. *European Journal of Lipid Science and Technology* **114(11)**:1254–1260 DOI [10.1002/ejlt.201100219](https://doi.org/10.1002/ejlt.201100219).
- Zhang K, Wang X, Liu Y. 2012.** Aqueous medium enzymatic preparation of L-alpha glycerylphosphorylcholine optimized by response surface methodology. *European Food Research and Technology* **234(3)**:485–491 DOI [10.1007/s00217-011-1655-x](https://doi.org/10.1007/s00217-011-1655-x).
- Zhao H, Sun L, Chen H, Xiang L, Chen D. 2020.** Intrinsic stability study of L- α -glycerylphosphorylcholine with HPLC method development and validation. *Journal of Pharmaceutical and Biomedical Analysis* **188**:113468 DOI [10.1016/j.jpba.2020.113468](https://doi.org/10.1016/j.jpba.2020.113468).
- Zhao YY, Xiong Y, Curtis JM. 2011.** Measurement of phospholipids by hydrophilic interaction liquid chromatography coupled to tandem mass spectrometry: the determination of choline containing compounds in foods. *Journal of Chromatography A* **1218(32)**:5470–5479 DOI [10.1016/j.chroma.2011.06.025](https://doi.org/10.1016/j.chroma.2011.06.025).
- Zimmerman T, Ibrahim SA. 2018.** Parallel colorimetric quantification of choline and phosphocholine as a method for studying choline kinase activity in complex mixtures. *Antibiotics* **7(1)**:24 DOI [10.3390/antibiotics7010024](https://doi.org/10.3390/antibiotics7010024).